A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants Save

Date Added
October 5th, 2018
PRO Number
Pro00081856
Researcher
Helmut Albrecht

List of Studies

Keywords
Drug Studies, HIV / AIDS, Infectious Diseases
Summary

The primary objective of this study is to evaluate the efficacy of switching from a regimen of 2 nucleos(t)ide reverse transcriptase inhibitors (NRTIs) and a third agent to a fixed dose combination (FDC) of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus continuing their baseline regimen in HIV-1 infected, virologically suppressed African American participants.

Institution
Palmetto
Recruitment Contact
Helmut Albrecht
803-540-1000
ClinicalTrialSurvey@PalmettoHealth.org

Change_preferences

-- OR --

Create_login